Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414317 · ClinicalTrials.gov registry record · NA
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
A NA study of Stage IV Bladder Cancer AJCC v8 and Stage III Bladder Cancer AJCC v8, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT06414317: Recruiting NA study of Stage IV Bladder Cancer AJCC v8 and Stage III Bladder Cancer AJCC v8, sponsored by Roswell Park Cancer Institute.
NCT06414317 is a NA study of Stage IV Bladder Cancer AJCC v8 and Stage III Bladder Cancer AJCC v8 that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 160 participants, above the 64-participant average among 7 other Stage IV Bladder Cancer AJCC v8 trials with a reported enrollment target (150% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414317, a NA study of Stage IV Bladder Cancer AJCC v8 and Stage III Bladder Cancer AJCC v8, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally advanced), to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Patients with advanced bladder cancer tend to be older, have multiple medical conditions and often have poor access to health care. An ENST may be an effective method to improve participation in treatment decision-making and care planning among patients with locally advanced, metastatic and unresectable bladder cancer and their caregivers.
Primary Outcome
A 12 item instrument used to determine how well employees feel they can implement the change in process .. Each item includes a scale from 1 (Disagree ) to 5 (Agree)
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Supportive Care
- PROCEDURE Assessment of Distress
- OTHER Consultation Visit
- OTHER Nutritional Assessment
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What NCT06414317 shows while recruiting
NCT06414317 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 7 other Stage IV Bladder Cancer AJCC v8 trials with a reported enrollment target (150% higher).
The record links to 5 conditions, with Stage IV Bladder Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.
NCT06414317 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06414317 about?
NCT06414317 is a clinical study titled "An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers". This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally advanced), to other places in the body (metastatic) or that cannot be re...
What is the current status of trial NCT06414317?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2024-01-12. Estimated completion is 2027-03-31.
What conditions does trial NCT06414317 study?
This clinical trial studies the following conditions: Stage IV Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma, Unresectable Bladder Carcinoma.
What interventions are being tested in trial NCT06414317?
The interventions under investigation include: Questionnaire Administration (OTHER), Supportive Care (OTHER), Assessment of Distress (PROCEDURE), Consultation Visit (OTHER), Nutritional Assessment (OTHER).
Who is sponsoring clinical trial NCT06414317?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414317 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Bladder Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
RECRUITING · Phase 4
-
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
RECRUITING · Phase 2
-
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
RECRUITING · Phase 2
-
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
RECRUITING · Phase 2
-
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 1
-
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI